|
The FDA last week rejected Biocon’s Bevacizumab, a biosimilar to Roche’s blockbuster
oncology drug Avastin, according to the Center for Biosimilars. Biocon gave few
details on the rejection, but it
likely stems from issues following an Aug. 22 manufacturing inspection.
Avastin was first approved in 2004 for the treatment of colorectal cancer, an
indication for which it currently holds covered or better status for 43% of
insured lives under the pharmacy benefit, and 86% under the medical benefit. |
|
SOURCE: MMIT Analytics,
as of 2/15/23 |
No comments:
Post a Comment